Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by F. Cappuzzo
The role of the molecular tumor board: learnings from the ROME trial
Abstract Precision Oncology transformed cancer therapy by personalizing treatment based on specific tumor molecular alterations. However, the increasing complexity of genomic and multi-omic data challenges clinical interpretation. Molecular Tumor Boards (MTBs) are critical for integrating expertise and translating genomic profiling into treatment recommendations.
483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC
Background: Atezo is an mAb that inhibits the interaction of PD-L1 with its receptors PD-1 and B7.1, thereby restoring tumor-specific T-cell immunity. Atezo monotherapy increases survival in patients (pts) with squamous (sq) and nonsquamous (nonsq) NSCLC across PD-L1 expression levels. The potential for chemo to further augment responses to atezo, with tolerable safety, has also been demonstrated.
Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
Background: Current treatments for advanced NSCLC include platinum (plat)-based doublet chemotherapy (chemo), pemetrexed (pem), bevacizumab, targeted drugs and programmed death-ligand 1 (PD-L1)/PD-1–targeted immunotherapy. Atezolizumab (atezo; anti-PDL1) inhibits binding of PD-L1 to PD-1 and B7.1 and restores anti-tumor T-cell activity.
Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
Background: An afatinib NPU program started in 2010 after the Phase 2b/3 LUX-Lung 1 trial demonstrated significantly improved progression-free survival and objective response rate (ORR) with afatinib versus placebo in advanced NSCLC patients following failure of E/G and 1–2 lines of chemotherapy.
Crizotinib: from discovery to accelerated development to front-line treatment
Non-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Background In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought to characterize the relationship between pembrolizumab dose, exposure, and response to define an effective dose for these patients. Patients and methods Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) (n = 55), 10 mg/kg Q3W (n = 238), or 10 mg/kg Q2W (n = 156). Response (RECIST v1.1) was assessed every 9 weeks.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small cell lung cancer
Background In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small cell lung cancer (NSCLC). We sought to characterize the relationship between pembrolizumab dose, exposure, and response to define an effective dose for these patients. Methods Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) (n=55), 10 mg/kg Q3W (n=238), or 10 mg/kg Q2W (n=156). Response (RECIST v1.1) was assessed every 9 weeks.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with F.
Contact F., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack